Icatibant

Nature Reviews Drug Discovery

Volumn 7, Issue 10, 2008, Pages 801-802

  Bork, Konrad ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; DX 88; DYAX; ECALLANTIDE; FIRAZYR; ICATIBANT; PLACEBO; RECOMBINANT COMPLEMENT COMPONENT C1S INHIBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; HOME CARE; HUMAN; LARYNX EDEMA; LONG TERM CARE; PRIORITY JOURNAL; RELAPSE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 53249154732     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2694     Document Type: Article

References (15)

1. Davis, A. E. 3rd. New treatments addressing the pathophysiology of hereditary angioedema. Clin. Mol. Allergy 6, 2 (2008).
2. Gompels, M. M. et al. C1 inhibitor deficiency: Consensus document. Clin. Exp. Immunol. 139, 379-394 (2005).
3. Nussberger, J. et al. Plasma bradykinin in angiooedema. Lancet 351, 1693-1697 (1998).
4. Marceau. F. & Regoli, D. Bradykinin receptor ligands: Therapeutic perspectives. Nature Rev. Drug Discov. 3, 845-852 (2004).
5. Hock, F. J. et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102, 769-773 (1991).
6. Wirth, K. et al. Hoe 140 a new potent and long acting bradykinin-antagonist: In vivo studies. Br. J. Pharmacol. 102 774-777 (1991).
7. European Medicines Agency (EMEA). European Public Assessment Report - Firazyr. EMEA web site [online], (2008).
8. Bork, K. et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 19, 1497-1503 (2007).
9. Bork, K. et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am. J. Med. 120, 987-992 (2007).
10. Bork, K. et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45, 1774-1784 (2005).
11. Schneider, L. et al. Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120, 416-422 (2007).
12. Choi, G. et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 47, 1028-1032 (2007).
13. IMS Health Analysis, IMS MIDAS Quantum (2008).
14. Hilliker, I. et al. Jerini (Credit Suisse Securities Europe, 27 Feb 2008).
15. White, B. Jerini (Deutsche Bank Biotechnology, 1 May 2008).